Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Role of MSC-derived galectin 3 in the AML microenvironment.

Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N Jr, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2018 Apr 12;1865(7):959-969. doi: 10.1016/j.bbamcr.2018.04.005. [Epub ahead of print]

PMID:
29655803
2.

Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.

Mattila JP, Mirandola L, Chiriva-Internati M.

J Biomed Mater Res B Appl Biomater. 2018 Mar 4. doi: 10.1002/jbm.b.34092. [Epub ahead of print]

PMID:
29504239
3.

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.

Schutt CA, Mirandola L, Figueroa JA, Nguyen DD, Cordero J, Bumm K, Judson BL, Chiriva-Internati M.

Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.

4.

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M.

Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.

5.

Stereo-EEG: Diagnostic and therapeutic tool for periventricular nodular heterotopia epilepsies.

Mirandola L, Mai RF, Francione S, Pelliccia V, Gozzo F, Sartori I, Nobili L, Cardinale F, Cossu M, Meletti S, Tassi L.

Epilepsia. 2017 Nov;58(11):1962-1971. doi: 10.1111/epi.13895. Epub 2017 Sep 7.

PMID:
28880999
6.

RF-ablation in periventricular heterotopia-related epilepsy.

Cossu M, Mirandola L, Tassi L.

Epilepsy Res. 2018 May;142:121-125. doi: 10.1016/j.eplepsyres.2017.07.001. Epub 2017 Jul 3.

PMID:
28705474
7.

AAV2/8-humanFOXP3 gene therapy shows robust anti-atherosclerosis efficacy in LDLR-KO mice on high cholesterol diet.

Cao M, Theus SA, Straub KD, Figueroa JA, Mirandola L, Chiriva-Internati M, Hermonat PL.

J Transl Med. 2015 Jul 18;13:235. doi: 10.1186/s12967-015-0597-7.

8.

An EEG-fMRI Study on the Termination of Generalized Spike-And-Wave Discharges in Absence Epilepsy.

Benuzzi F, Ballotta D, Mirandola L, Ruggieri A, Vaudano AE, Zucchelli M, Ferrari E, Nichelli PF, Meletti S.

PLoS One. 2015 Jul 8;10(7):e0130943. doi: 10.1371/journal.pone.0130943. eCollection 2015.

9.

A one-year prospective study of refractory status epilepticus in Modena, Italy.

Giovannini G, Monti G, Polisi MM, Mirandola L, Marudi A, Pinelli G, Valzania F, Girardis M, Nichelli PF, Meletti S.

Epilepsy Behav. 2015 Aug;49:141-5. doi: 10.1016/j.yebeh.2015.05.022.

PMID:
26074182
10.

PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation.

Platonova N, Manzo T, Mirandola L, Colombo M, Calzavara E, Vigolo E, Cermisoni GC, De Simone D, Garavelli S, Cecchinato V, Lazzari E, Neri A, Chiaramonte R.

Genes Chromosomes Cancer. 2015 Jun 6. doi: 10.1002/gcc.22264. [Epub ahead of print]

PMID:
26052821
11.

Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis.

Colombo M, Mirandola L, Reidy A, Suvorava N, Konala V, Chiaramonte R, Grizzi F, Rahman RL, Jenkins MR, Nugyen DD, Dalhbeck S, Cobos E, Figueroa JA, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):188-99. doi: 10.3109/08830185.2015.1027629. Review.

12.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Review.

PMID:
25901860
13.

Cancer-testis antigens and immunotherapy in the light of cancer complexity.

Grizzi F, Mirandola L, Qehajaj D, Cobos E, Figueroa JA, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):143-53. doi: 10.3109/08830185.2015.1018418. Review.

PMID:
25901859
14.

Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium.

Mirandola L, Wade R, Verma R, Pena C, Hosiriluck N, Figueroa JA, Cobos E, Jenkins MR, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):134-42. doi: 10.3109/08830185.2015.1018417. Review.

PMID:
25901858
15.

Long-term surgery outcome for epilepsy and psychogenic nonepileptic seizures in a child with anterior cingulate gyrus dysplasia.

Mirandola L, Meletti S, Cantalupo G.

Epilepsy Behav Case Rep. 2015 Feb 24;3:20-2. doi: 10.1016/j.ebcr.2015.01.002. eCollection 2015.

16.

Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.

Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, Jenkins MR, Cobos E, Jumper C, Alalawi R, Chiriva-Internati M.

Oncotarget. 2015 Feb 20;6(5):2812-26.

17.

Galectins in cancer: carcinogenesis, diagnosis and therapy.

Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M.

Ann Transl Med. 2014 Sep;2(9):88. doi: 10.3978/j.issn.2305-5839.2014.09.12. Review.

18.

Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.

Pena C, Mirandola L, Figueroa JA, Hosiriluck N, Suvorava N, Trotter K, Reidy A, Rakhshanda R, Payne D, Jenkins M, Grizzi F, Littlefield L, Chiriva-Internati M, Cobos E.

Ann Transl Med. 2014 Sep;2(9):87. doi: 10.3978/j.issn.2305-5839.2014.09.14. Review.

19.

Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.

Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M.

Gynecol Oncol. 2014 Dec;135(3):573-9. doi: 10.1016/j.ygyno.2014.09.021. Epub 2014 Oct 6.

PMID:
25284038
20.

Editorial: international reviews of immunology.

Internati MC, Mirandola L, Bot A.

Int Rev Immunol. 2014 Oct;33(5):365-6. doi: 10.3109/08830185.2014.941239. No abstract available.

PMID:
25277338
21.

Notch signaling drives multiple myeloma induced osteoclastogenesis.

Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R.

Oncotarget. 2014 Nov 15;5(21):10393-406.

22.

Selective expression and immunogenicity of the cancer/testis antigens SP17, AKAP4 and PTTG1 in non-small cell lung cancer: new candidates for active immunotherapy.

Chiriva-Internati M, Mirandola L, Figueroa JA, Yu Y, Grizzi F, Kim M, Jenkins M, Cobos E, Jumper C, Alalawi R.

Chest. 2014 May 8. doi: 10.1378/chest.13-0770. [Epub ahead of print]

PMID:
24811938
23.

The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review.

Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, Aulakh A, Konala V, Verma R, Riaz J, Wade R, Saadeh C, Rahman RL, Pandey A, Radhi S, Nguyen DD, Jenkins M, Chiriva-Internati M, Cobos E.

Int Rev Immunol. 2014 Oct;33(5):383-401. doi: 10.3109/08830185.2014.911857. Epub 2014 May 8. Review.

PMID:
24811210
24.

Sperm protein 17 is an oncofetal antigen: a lesson from a murine model.

Arnaboldi F, Menon A, Menegola E, Di Renzo F, Mirandola L, Grizzi F, Figueroa JA, Cobos E, Jenkins M, Barajon I, Chiriva-Internati M.

Int Rev Immunol. 2014 Oct;33(5):367-74. doi: 10.3109/08830185.2014.911856. Epub 2014 May 8. Review.

PMID:
24811209
25.

Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?

Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2014 Oct;33(5):417-27. doi: 10.3109/08830185.2014.911855. Epub 2014 May 6. Review.

PMID:
24801755
26.

Comparison of efficacy of the disease-specific LOX1- and constitutive cytomegalovirus-promoters in expressing interleukin 10 through adeno-associated virus 2/8 delivery in atherosclerotic mice.

Zhu H, Cao M, Mirandola L, Figueroa JA, Cobos E, Chiriva-Internati M, Hermonat PL.

PLoS One. 2014 Apr 15;9(4):e94665. doi: 10.1371/journal.pone.0094665. eCollection 2014.

27.

Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.

Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N, Lazzari E, Lancellotti M, Bulfamante G, Cobos E, Chiriva-Internati M, Chiaramonte R.

Leukemia. 2013 Jul;27(7):1558-66. doi: 10.1038/leu.2013.27. Epub 2013 Jan 28.

PMID:
23354012
28.

Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.

Colombo M, Mirandola L, Platonova N, Apicella L, Basile A, Figueroa AJ, Cobos E, Chiriva-Internati M, Chiaramonte R.

Leukemia. 2013 Apr;27(5):1009-18. doi: 10.1038/leu.2013.6. Epub 2013 Jan 11. Review.

PMID:
23307030
29.

Centrotemporal spikes during NREM sleep: The promoting action of thalamus revealed by simultaneous EEG and fMRI coregistration.

Mirandola L, Cantalupo G, Vaudano AE, Avanzini P, Ruggieri A, Pisani F, Cossu G, Tassinari CA, Nichelli PF, Benuzzi F, Meletti S.

Epilepsy Behav Case Rep. 2013 Jul 27;1:106-9. doi: 10.1016/j.ebcr.2013.06.005. eCollection 2013.

30.

Aging, cancer, and cancer vaccines.

Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E, Chiriva-Internati M.

Immun Ageing. 2012 Apr 17;9(1):4. doi: 10.1186/1742-4933-9-4.

31.

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.

Schutt C, Bumm K, Mirandola L, Bernardini G, Cunha N, Tijani L, Nguyen D, Cordero J, Jenkins MR, Cobos E, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2012 Feb;31(1):22-42. doi: 10.3109/08830185.2011.637253. Review.

32.

Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.

Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, D'Cunha N, Tijani L, Hardwick F, Nguyen D, Kast WM, Cobos E.

Int Rev Immunol. 2012 Feb;31(1):3-21. doi: 10.3109/08830185.2011.637254. Review.

33.

Increased cortical BOLD signal anticipates generalized spike and wave discharges in adolescents and adults with idiopathic generalized epilepsies.

Benuzzi F, Mirandola L, Pugnaghi M, Farinelli V, Tassinari CA, Capovilla G, Cantalupo G, Beccaria F, Nichelli P, Meletti S.

Epilepsia. 2012 Apr;53(4):622-30. doi: 10.1111/j.1528-1167.2011.03385.x. Epub 2012 Jan 13.

34.

Application of vitamin D and derivatives in hematological malignancies.

Kim M, Mirandola L, Pandey A, Nguyen DD, Jenkins MR, Turcel M, Cobos E, Chiriva-Internati M.

Cancer Lett. 2012 Jun 1;319(1):8-22. doi: 10.1016/j.canlet.2011.10.026. Epub 2011 Dec 19. Review.

PMID:
22193723
35.

Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.

Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, Asselta R, Paraboschi EM, Comi P, Chiaramonte R.

J Pathol. 2012 Apr;226(5):713-22. doi: 10.1002/path.3015. Epub 2011 Dec 9.

PMID:
21984373
36.

Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.

Mirandola L, Yu Y, Jenkins MR, Chiaramonte R, Cobos E, John CM, Chiriva-Internati M.

BMC Cancer. 2011 Sep 16;11:394. doi: 10.1186/1471-2407-11-394.

37.

Non-convulsive status epilepticus of frontal origin as the first manifestation of Hashimoto's encephalopathy.

Monti G, Pugnaghi M, Ariatti A, Mirandola L, Giovannini G, Scacchetti S, Nichelli P, Meletti S.

Epileptic Disord. 2011 Sep;13(3):253-8. doi: 10.1684/epd.2011.0457.

38.

Diffusion-Weighted Imaging in the Early Diagnosis of EBV Meningoencephalitis. A Case Report.

De Simone M, Rocca R, Mirandola L.

Neuroradiol J. 2011 Aug 31;24(4):551-3. Epub 2011 Sep 2.

PMID:
24059711
39.

Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.

Mirandola L, Yu Y, Chui K, Jenkins MR, Cobos E, John CM, Chiriva-Internati M.

PLoS One. 2011;6(7):e21811. doi: 10.1371/journal.pone.0021811. Epub 2011 Jul 13.

40.

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.

Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E.

J Immunother. 2011 Jul-Aug;34(6):490-9. doi: 10.1097/CJI.0b013e31821ca76f.

PMID:
21654522
41.

Notch-ing from T-cell to B-cell lymphoid malignancies.

Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R.

Cancer Lett. 2011 Sep 1;308(1):1-13. doi: 10.1016/j.canlet.2011.05.009. Review.

PMID:
21652011
42.

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.

Mirandola L, J Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):127-37. doi: 10.3109/08830185.2011.572504. Review.

PMID:
21557639
43.

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.

Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Review.

PMID:
21557635
44.

Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.

Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM.

Prostate. 2012 Jan;72(1):12-23. doi: 10.1002/pros.21400. Epub 2011 Apr 25.

PMID:
21520158
45.

Recognition of emotions from faces and voices in medial temporal lobe epilepsy.

Bonora A, Benuzzi F, Monti G, Mirandola L, Pugnaghi M, Nichelli P, Meletti S.

Epilepsy Behav. 2011 Apr;20(4):648-54. doi: 10.1016/j.yebeh.2011.01.027. Epub 2011 Apr 1.

PMID:
21459049
46.

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM.

PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471.

47.

Clinical features of seizures associated with parahippocampal/inferior temporal lesions compared to those with hippocampal sclerosis.

Mirandola L, Badawy RA, Saunders AM, McIntosh A, Berkovic SF, Jackson GD.

Epilepsia. 2010 Sep;51(9):1906-9. doi: 10.1111/j.1528-1167.2010.02537.x.

48.

Burkitt lymphoma translocation turns Notch over to the dark side.

Mirandola L, Basile A, Comi P, Chiaramonte R.

Leuk Res. 2009 Jun;33(6):750-1. doi: 10.1016/j.leukres.2008.10.002. Epub 2008 Nov 12. No abstract available.

PMID:
19007986
49.

Down-regulation of Notch1 expression is involved in HL-60 cell growth inhibition induced by 4-hydroxynonenal, a product of lipid peroxidation.

Pizzimenti S, Barrera G, Calzavara E, Mirandola L, Toaldo C, Dianzani MU, Comi P, Chiaramonte R.

Med Chem. 2008 Nov;4(6):551-7.

PMID:
18991739
50.

Modulation by Acanthospermum australe extracts of the tumor induced hematopoietic changes in mice.

Mirandola L, Justo GZ, Queiroz ML.

Immunopharmacol Immunotoxicol. 2002 May;24(2):275-88.

PMID:
12066853

Supplemental Content

Loading ...
Support Center